VBLT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VBLT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Vascular Biogenics's quick ratio for the quarter that ended in Jun. 2023 was 4.63.
Vascular Biogenics has a quick ratio of 4.63. It generally indicates good short-term financial strength.
The historical rank and industry rank for Vascular Biogenics's Quick Ratio or its related term are showing as below:
During the past 11 years, Vascular Biogenics's highest Quick Ratio was 13.12. The lowest was 1.50. And the median was 6.45.
The historical data trend for Vascular Biogenics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vascular Biogenics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Quick Ratio | Get a 7-Day Free Trial | 10.83 | 4.36 | 4.29 | 5.53 | 3.29 |
Vascular Biogenics Quarterly Data | ||||||||||||||||||||
Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Quick Ratio | Get a 7-Day Free Trial | 4.05 | 2.82 | 3.29 | 3.48 | 4.63 |
For the Biotechnology subindustry, Vascular Biogenics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Vascular Biogenics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Vascular Biogenics's Quick Ratio for the fiscal year that ended in Dec. 2022 is calculated as
Quick Ratio (A: Dec. 2022 ) | = | (Total Current Assets | - | Total Inventories) | / | Total Current Liabilities |
= | (22.149 | - | 0) | / | 6.731 | |
= | 3.29 |
Vascular Biogenics's Quick Ratio for the quarter that ended in Jun. 2023 is calculated as
Quick Ratio (Q: Jun. 2023 ) | = | (Total Current Assets | - | Total Inventories) | / | Total Current Liabilities |
= | (24.548 | - | 0) | / | 5.301 | |
= | 4.63 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vascular Biogenics (NAS:VBLT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of Vascular Biogenics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Builders Vc Fund I, L.p. | 10 percent owner | 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105 |
James Jimin Kim | 10 percent owner | C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404 |
B Capital Group Management, L.p. | 10 percent owner | 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
B Capital Group Investors Ii Ltd. | 10 percent owner | 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
B Capital Group Partners Ii, L.p. | 10 percent owner | 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
Joseph P Wagner | officer: Chief Scientific Officer | 320 HATCH DRIVE, FOSTER CITY CA 94404 |
Tuomo Patsi | director | 320 HATCH DRIVE, FOSTER CITY NY 94404 |
Thomas Bock | director, officer: Chief Executive Officer | 320 HATCH DRIVE, FOSTER CITY NY 94404 |
Michele Galen | director | 320 HATCH DRIVE, FOSTER CITY CA 94404 |
Fr Capital Holdings, L.p. | 10 percent owner | 2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103 |
B Capital Fund Ii, L.p. | 10 percent owner | C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266 |
Builders Vc Fund I (canada), L.p. | 10 percent owner | 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105 |
Builders Vc Entrepreneurs Fund I, L.p. | 10 percent owner | 201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105 |
Dubin Thomas I H | director | C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Peter Feinberg | director | C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-19-2022
By Business Wire Business Wire • 02-27-2023
By Ds*** Ds*** • 09-01-2022
By GuruFocusNews GuruFocusNews • 06-06-2022
By Marketwired • 10-12-2023
By GuruFocusNews GuruFocusNews • 06-20-2022
By Business Wire Business Wire • 02-23-2023
By GuruFocusNews GuruFocusNews • 06-16-2022
By GuruFocusNews GuruFocusNews • 06-29-2022
By Marketwired • 10-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.